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Background: The epithelial-to-mesenchymal transition (EMT) accompanied by the downregulation of E-cadherin
has been thought to promote metastasis. Cyclooxygenase-2 (Cox-2) is presumed to contribute to cancer progression
through its multifaceted function, and recently its inverse relationship with E-cadherin was suggested. The aim of the
present study was to investigate whether selective Cox-2 inhibitors restore the expression of E-cadherin in head and
neck squamous cell carcinoma (HNSCC) cells, and to examine the possible correlations of the expression levels of EMT-
related molecules with clinicopathological factors in HNSCC.
Methods: We used quantitative real-time PCR to examine the effects of three selective Cox-2 inhibitors, i.e., celecoxib,
NS-398, and SC-791 on the gene expressions of E-cadherin (CDH-1) and its transcriptional repressors (SIP1, Snail, Twist)
in the human HNSCC cell lines HSC-2 and HSC-4. To evaluate the changes in E-cadherin expression on the cell surface,
we used a flowcytometer and immunofluorescent staining in addition to Western blotting. We evaluated and
statistically analyzed the clinicopathological factors and mRNA expressions of Cox-2, CDH-1 and its repressors in surgical
specimens of 40 patients with tongue squamous cell carcinoma (TSCC).
Results: The selective Cox-2 inhibitors upregulated the E-cadherin expression on the cell surface of the HNSCC cells
through the downregulation of its transcriptional repressors. The extent of this effect depended on the baseline
expression levels of both E-cadherin and Cox-2 in each cell line. A univariate analysis showed that higher Cox-2 mRNA
expression (p = 0.037), lower CDH-1 mRNA expression (p = 0.020), and advanced T-classification (p = 0.036) were
significantly correlated with lymph node metastasis in TSCC. A multivariate logistic regression revealed that lower CDH-1
mRNA expression was the independent risk factor affecting lymph node metastasis (p = 0.041).
Conclusions: These findings suggest that the appropriately selective administration of certain Cox-2 inhibitors may
have an anti-metastatic effect through suppression of the EMT by restoring E-cadherin expression. In addition, the
downregulation of CDH-1 resulting from the EMT may be closely involved in lymph node metastasis in TSCC.
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Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer with an annual incidence
of over 560,000 cases worldwide [1]. Despite various ad-
vances in combined modality therapy, the survival rate
of HNSCC patients has not improved over the past two
decades, due largely to the uncontrollable metastasis to
lymph nodes and distant organs [2]. Cervical lymph
node metastasis in particular has been considered the
most important adverse prognostic factor in HNSCC
[3-5]. More effective strategies based on a better under-
standing of the molecular mechanisms that lead to me-
tastasis are thus indispensable.
Recent progress in tumor biology indicates that the
initial steps during the sequential process of metastasis
are notably analogous to the epithelial-to-mesenchymal
transition (EMT) in which cells lose epithelial features
including cell adhesion and gain mesenchymal traits in-
cluding cell motility during embryogenesis and wound
healing [6,7]. In the tumor context, the acquisition of
the EMT, accompanied by functional loss of E-cadherin
that maintains intercellular adhesion, stimulates the dis-
semination of single tumor cells from primary sites
through the loss of cell-to-cell contact, thereby endowing
cells with metastatic abilities [6-8]. At the transcriptional
level, E-cadherin is downregulated by several transcrip-
tional repressors including snail, slug, DeltaEF1/ZEB1,
SIP1 (Smad interacting protein 1)/ZEB2, E12/E47, and
twist, by binding to E-box promoter elements of CDH-1, a
gene encoding human E-cadherin [6-8]. We recently re-
ported that SIP1 expression was inversely correlated with
E-cadherin expression in HNSCC cells, and that the
downregulation of E-cadherin and upregulated nuclear
localization of SIP1 were independently correlated with
delayed neck metastasis in stage I/II tongue squamous cell
carcinoma (TSCC) [9]. However, a practical therapeutic
approach that leads to the suppression of the EMT has
not been developed to control the progression of cancers,
including HNSCC.
Cyclooxygenase-2 (Cox-2), an isoform of the Cox en-
zymes inducible in response to proinflammatory cyto-
kines and growth factors, catalyzes the biosynthesis of
prostanoids including prostaglandin E2 (PGE2), thereby
playing important roles in the regulation of various cellu-
lar functions under physiologic and pathologic conditions
including carcinogenesis [10-13]. Increased expression of
Cox-2 has been found in a variety of human malignancies,
including HNSCC [14-16]. Previous studies have reported
several mechanisms by which Cox-2 contributes to car-
cinogenesis as well as cancer progression, including the
activation of carcinogens [17], resistance to apoptosis
[18,19], immunosuppression [20,21], the promotion of
angiogenesis [11,22], the stimulation of proliferation [23]
and invasiveness [24], and the autocrine activity ofestrogen [25]. Such a multifaceted function of Cox-2 in
conferring the malignant phenotype strongly suggested
that Cox-2 is an attractive preventive and therapeutic tar-
get for various cancers [12,13,26-29]. A number of clinical
trials have been carried out to examine the benefit of
Cox-2 inhibitors, such as celecoxib, in the chemopreven-
tion of premalignant lesions such as familial adenoma
polyposis (FAP) [30], Barrett’s esophagus [31], and oral
premalignant lesions [32], as well as in the treatment of
advanced cancers in combination with chemotherapy
[33-36]. However, these trials could demonstrate neither
a significant chemopreventive effect nor any additional
therapeutic effect of celecoxib on clinical outcomes, ex-
cept in FAP, suggesting that the optimal applications of
Cox-2 inhibitors should be reconsidered, and that further
research is necessary regarding the various mechanisms
underlying the anti-cancer effects of Cox-2 inhibitors
against tumors.
An inverse relationship between E-cadherin and Cox-2
and its molecular mechanism in cancer cells was first
shown in non-small cell lung cancer (NSCLC), in which
Cox-2 overexpression led to decreased E-cadherin expres-
sion through the upregulation of PGE2 and transcriptional
repressors of E-cadherin, whereas the inhibition of Cox-2
showed an inverse regulation of those molecules [37]. A
similar effect of Cox-2 inhibitors that reverse the EMT by
restoring E-cadherin expression was also found in subsets
of colon, gastric, and bladder cancer cells [38-43]. How-
ever, in HNSCC, neither the effect of Cox-2 inhibitors on
the regulation of E-cadherin expression nor its specific
mechanism has been examined to date, except for a study
that investigated interleukin-1β (IL-1β)-induced upregula-
tion of Snail leading to EMT [44].
We conducted the present study to determine whether
selective Cox-2 inhibitors restore the expression of E-
cadherin through the downregulation of its transcrip-
tional repressors to suppress the EMT in HNSCC cells,
and to determine whether the gene expression levels of
the molecules that are implicated in the EMT are corre-
lated with clinicopathological parameters in HNSCC.
Methods
Cell culture
We used six cell lines established from human HNSCC:
HSC-2 derived from the floor of the mouth; HSC-3, HSC-
4, and SAS from the tongue; and KB and FaDu from the
pharynx. The human fibrosarcoma cell line HT-1080 was
used as the negative control for E-cadherin expression.
The cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (HSC-2, HSC-3, HSC-4, KB, and
FaDu), or a mixture of DMEM and Ham’s F-12 (SAS), or
minimal essential medium (HT-1080), supplemented with
10% fetal bovine serum (FBS) in a humidified incubator
(37°C, 5% CO2).
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HSC-2 and HSC-4 cells were seeded in six-well plates at
a density of 2 × 105 cells per well and incubated over-
night in 10% FBS medium. The cells were then treated
with different selective Cox-2 inhibitors: 50 μM of cele-
coxib (Toronto Research Chemicals, Toronto, Ontario,
Canada), 80 μM of NS-398 (Cayman Chemical, Ann
Arbor, MI, USA), or 20 μM of SC-791 (Calbiochem,
Darmstadt, Germany). These concentrations of each
Cox-2 inhibitor were found to be optimal with no toxic
effect on cell viability up to 48 h based on our prelimin-
ary experiments for this purpose. Treatments with only
dimethyl sulfoxide (DMSO) (Nacalai Tesque, Kyoto,
Japan) used as a solvent for the inhibitors were set as
the control. For the evaluation of changes in gene ex-
pression associated with Cox-2 inhibition, total RNA
was extracted after a 12-h incubation.
Quantitative real-time PCR
Total RNA from cell lines or fresh frozen tissues was
isolated using Trizol reagent (Invitrogen, Carlsbad, CA)
and reverse-transcribed into cDNA using random hex-
amer primer and SuperScript II reverse transcriptase
(Invitrogen) according to the manufacturer’s instruc-
tions. Quantitative real-time polymerase chain reaction
(PCR) was performed using the 7500 Fast Real-Time
PCR system instrument and software (Applied Biosys-
tems, Foster City, CA) following the manufacturer’s
protocol. Specific primers and probes were obtained
from Applied Biosystems as TaqMan® Gene Expression
Assays, with the following IDs: human E-cadherin/CDH-
1, Hs00170423_m1; Snail/SNAI1, Hs00195591_m1; SIP1/
ZFHX1B, Hs00207691_m1; twist/TWIST1, Hs00361186_
m1; Cox-2/PTGS2, Hs01573471_m1; and GAPDH (glyc-
eraldehyde-3-phosphate dehydrogenase)/GAPDH, Hs9999
9905_m1. The PCR amplification conditions were: 20 s at
95°C followed by 40 cycles of 3 s denaturation at 95°C and
30 s annealing at 60°C. We quantified the relative expres-
sion levels of the genes by the standard curve method, and
we compared the levels after normalization using those of
GAPDH used as an endogenous control.
Flowcytometric analysis
For the quantitative analysis of E-cadherin expression at
protein level, we harvested cells that had been treated
with each of the selective Cox-2 inhibitors for 24 h,
using a cell dissociation solution (C 5914, Sigma-Aldrich,
St. Louis, MO). Based on our preliminary experiments for
this purpose, we identified the following optimal concen-
trations of each Cox-2 inhibitor: 25 μM of celecoxib,
40 μM of NS-398, and 10 μM of SC-791. After blocking
incubation in 0.5% bovine serum albumin (BSA) in 1 ×
phosphate-buffered saline (PBS) for 10 min, we labeled
the cells with PE-conjugated anti-human E-Cadherinantibody (BioLegend, San Diego, CA) for 1 h, followed by
DNA staining using 7-AAD Viability Dye (Beckman
Coulter, Indianapolis, IN) for 5 min. Control cells were la-
beled with PE-conjugated mouse IgG1, κ isotype ctrl (Bio-
Legend). We then analyzed the E-cadherin expression on
the cells using the Epics XL-MCL™ Flow Cytometer
(Beckman Coulter). Data are presented as the median,
mean, and mode of fluorescence intensity of the cells
counted.
Western blotting
The cells treated under the same conditions as those for
flowcytometry were lysed in lysis buffer (50 mM Tris pH
7.5, 5 mM EDTA, 150 mM NaCl, 1% Triton-X100) con-
taining 1 mM PMSF, 10 μg/ml leupeptin, 1 μg/ml pep-
statin, 1 mU/ml aprotinin, 50 mM sodium fluoride, 2
mM sodium orthovanadate, and 50 nM Calculin A (Cell
signaling). The protein concentration in the cell lysates
was determined by the Bradford protein assay (Bio-Rad).
Twenty μg of total proteins were separated by SDS-PAGE
and transferred to polyvinylidene difluoride membranes
(Amersham). The membranes were blocked with 5% skim
milk in PBS containing 0.1% Tween 20, and probed with
mouse anti-E-cadherin antibody (BD Biosciences) at
1:1000 dilution overnight at 4°C. Subsequently, the mem-
branes were incubated with horseradish peroxidase-
conjugated anti-mouse IgG sheep antibody (Amersham)
for 1 h. The reactive proteins were visualized using
ECL-plus (Amersham) according to the manufacturer’s
instructions. Equal loading of proteins was confirmed
by probing the membranes with mouse anti- β-actin
antibody (Sigma).
Immunofluorescent staining
HSC-2 cells for immunofluorescent staining of E-cadherin
were seeded in slide chambers (IWAKI, Tokyo, Japan) and
treated with 25 μM of celecoxib or DMSO for 24 h.
After washing the cells extensively with PBS, we fixed
the cells with cold methanol for 10 min at -20°C. After
washing with PBS, the cells were incubated with Alexa
Fluor 488-conjugated anti-E-cadherin antibody (Santa
Cruz Biotechnology, Dallas, TX) at 1:200 dilution in PBS
for 1 h. The nuclei were visualized by staining with
Hoechst 33258 (Sigma-Aldrich). Stained cells were then
mounted with Prolong Gold Antifade Reagent (Invitrogen).
The fluorescent images were captured through a fluores-
cence microscope (Olympus, Tokyo, Japan).
Patients and tissue samples
Human tissue specimens were obtained from patients
with histologically verified tongue squamous cell carcin-
oma (TSCC) who underwent primary surgery at the
Department of Otorhinolaryngology–Head and Neck Sur-
gery, Keio University Hospital (Tokyo, Japan) between
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proval from our Institutional Ethics Review Board were
obtained for the use of the clinical materials in the present
study. Materials from patients who had received chemo-
therapy or radiotherapy prior to surgery or who previously
had double cancer in the head and neck region were
excluded from the study.
In addition to formalin fixation for routine histopatho-
logical diagnosis, fresh tumor tissues and, when possible,
noncancerous mucosal tissues distant from the TSCC le-
sion were collected immediately after resection, placed
separately in an RNA stabilization regent (RNAlater,
Qiagen, Valencia, CA), and stored at −80°C until further
analysis. For this study, 40 patients were selected on the
basis of the availability of frozen tissue from which RNA
of sufficient quality could be extracted. The clinicopath-
ological characteristics of the patients were collected
from the medical records, and the tumor stages were
classified according to the American Joint Committee
on Cancer TNM staging system. We evaluated the histo-
pathological characteristics of the tumor specimens (i.e.,
histological grade [differentiation], vascular invasion,
lymphatic invasion, and perineural invasion) by review-
ing each slide stained with hematoxylin and eosin.
Statistical analysis
The data obtained in the in vitro experiments are pre-
sented as mean ± standard deviation (SD). The mRNA
expression levels of CDH1, SIP1, Snail, Twist, and Cox2
in the clinical samples are indicated as median values
and ranges because of the skewed distribution of the
data. Differences in the mRNA expression levels between
paired samples (tumor vs. noncancerous) were assessed
using the Wilcoxon signed rank-sum test. Correlations
between the mRNA expression levels and clinicopatho-



























Figure 1 Baseline mRNA expression of Cox-2, CDH-1 and its transcrip
each gene in the HNSCC cell lines were assessed by quantitative real-time
value by that of SAS as a calibrator for convenience. A: Cox-2 and CDH-1. B
was found between Cox-2 and CDH-1 (rs = −0.714, p = 0.055), SIP1 was sho
inversely correlate with CDH-1 (rs = −0.886, p = 0.024) by Spearman rank coU-test or the Spearman rank correlation coefficient. Risk
factors of lymph node metastasis were examined using
Fisher’s exact test, the chi-square test, or the Mann-
Whitney U-test for the univariate analysis, and a multiple
logistic regression model with the stepwise selection
method for the multivariate analysis. P-values less than
0.05 were considered statistically significant. All statistical
analyses were performed using SPSS Ver. 16.0.Results
Baseline mRNA expression of Cox-2, CDH-1, and its
transcriptional repressors in HNSCC Cells
We used quantitative real-time PCR to evaluate the
mRNA expression levels of Cox-2, E-cadherin transcripts
(CDH-1) and its transcriptional repressors (SIP1, Snail,
and Twist) in HNSCC cell lines. The relative expression
levels of each gene were normalized by dividing each value
by that of SAS cells as a calibrator for convenience. As
shown in Figure 1A, a trend toward an inverse correlation
was found between Cox-2 and CDH-1 by Spearman
rank correlation coefficient (rs = −0.714, p = 0.055). HT-
1080 cells showed no CDH-1 expression as expected as
the negative control for E-cadherin. Figure 1B displays
the relative expression levels of the transcriptional re-
pressors. Interestingly, the expression level of SIP1 was
revealed to be significantly correlated with that of Cox-
2 (rs = 0.771, p = 0.042) and inversely correlated with
that of CDH-1 (rs = −0.886, p = 0.024), whereas those of
Snail and Twist were shown to correlate with neither
Cox-2 nor CDH-1.
Based on these baseline mRNA expression levels, we
selected the following cells for the in vitro experiments:
HSC-2 expressing a relatively high level of Cox-2 and a
low level of CDH-1, and HSC-4 expressing a relatively

























SIP1 Snail Twist 
tional repressors in HNSCC cells. The mRNA expression levels of
PCR. The relative expression levels were normalized by dividing each
: SIP1, Snail, and Twist. While a trend toward an inverse correlation
wn to significantly correlate with Cox-2 (rs = 0.771, p = 0.042) and to
rrelation coefficient.
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transcriptional repressors by Cox-2 inhibition
We examined the effect of Cox-2 inhibition on the
mRNA expressions of CDH-1 and its transcriptional re-
pressors in the cell lines HSC-2 and HSC-4, using the
three selective Cox-2 inhibitors celecoxib, NS-398, and
SC-791. As regards the dose and exposure time of Cox-2
inhibitor, because we observed neither time-dependent
nor dose-dependent manner in the regulation with each
Cox-2 inhibitor in our preliminary experiments, the re-
sults were shown with the doses and exposure times
considered to be optimal for each Cox-2 inhibitor and
each purpose. In the HSC-2 cells, Cox-2 inhibition up-
regulated the CDH-1 expression compared to DMSO
treatment as the control, increasing by 1.60-, 1.93-, and
1.20-fold with celecoxib, NS-398, and SC-791, respec-
tively (Figure 2A). In contrast, Cox-2 inhibition in the
HSC-4 cells resulted in relatively less upregulation of
CDH-1 expression (Figure 2B). These results suggest that
the extent of the effect of Cox-2 inhibition may vary de-
pending on the cell type and presumably on the baseline
expression levels of both CDH-1 and Cox-2 in each cell.
In line with these results, all three transcriptional re-
pressors of E-cadherin were clearly downregulated in the























































Figure 2 Alterations in the mRNA expression of CDH-1 and its transcrip
the mRNA expressions of CDH-1 and its transcriptional repressors (SIP1, Snail,
different selective Cox-2 inhibitors: celecoxib, NS-398, and SC-791. A: In HSC-2
DMSO treatment as the control. B: In HSC-4 cells, Cox-2 inhibition resulted in
transcriptional repressors were clearly downregulated by each of the Cox-2 in
downregulation of these transcriptional repressors.decreasing by 0.18–0.34-, 0.15–0.32-, and 0.35–0.47-fold
in SIP1, Snail, and Twist, respectively (Figure 2C),
whereas the Cox-2 inhibition in the HSC-4 cells led to
relatively less downregulation of these transcriptional re-
pressors (Figure 2D).
Restoration of membranous E-cadherin expression by
Cox-2 inhibition
The Cox-2 inhibition-induced upregulation of E-cadherin in
the HNSCC cells at protein level was confirmed by Western
blotting (Figure 3A). In accord with its mRNA expressions,
E-cadherin expression in the HSC-2 cells was noticeably
enhanced by each of the Cox-2 inhibitors compared to
DMSO treatment, whereas relatively less upregulation of
E-cadherin expression was shown in the HSC-4 cells.
Because the function of E-cadherin in intercellular ad-
hesion is maintained through the membranous localiza-
tion of this molecule, we also evaluated the alteration of
its protein expression on the cell surface using a flow-
cytometer. In line with aforementioned results, Cox-2 in-
hibition elevated the cell surface expression of E-cadherin
compared to DMSO treatment in the HSC-2 cells, in-
creasing by more than 1.76-, 1.47-, and 1.21-fold with
celecoxib, NS-398, and SC-791, respectively (Figure 3B
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Figure 3 Restoration of membranous E-cadherin expression by Cox-2 inhibition. The alteration of E-cadherin protein expression following
Cox-2 inhibition was evaluated using the selective Cox-2 inhibitors: celecoxib, NS-398, and SC-791. A: Western blot displayed that Cox-2 inhibition
remarkably upregulated the protein expression of E-cadherin in HSC-2 cells compared to DMSO treatment as the control, whereas relatively less
upregulation of E-cadherin was shown in HSC-4 cells. (Lane 1, DMSO; 2, Celecoxib 25 μM; 3, NS-398 40 μM; 4, SC-791 10 μM) B: E-cadherin expression
on the cell surface was analyzed by flowcytometry. In HSC-2 cells, Cox-2 inhibition elevated the membranous expression of E-cadherin compared to
DMSO treatment as the control. C: Cox-2 inhibition in HSC-4 cells resulted in a slight increase of E-cadherin expression. D: Histograms of the
membranous expression of E-cadherin in HSC-2 cells with or without Cox-2 inhibition. E: Phase contrast images and immunofluorescent E-cadherin
staining of HSC-2 cells. Cox-2 inhibition with celecoxib resulted in the restoration of the epithelial morphology to a polygonal shape, and enhanced
intercellular expression of E-cadherin. Scale bar: 20 μm.
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less than 1.10-fold with any of the inhibitors (Figure 3C).
The cellular morphology and the localization of E-
cadherin expression in the HSC-2 cells were further
evaluated by a phase contrast microscope and immuno-
fluorescent staining, respectively. As shown in Figure 3E,
Cox-2 inhibition with celecoxib resulted in the restor-
ation of the epithelial morphology to a polygonal shape,
and enhanced intercellular expression of E-cadherin
compared to DMSO treatment.
Comparison of the mRNA expressions of Cox-2 and CDH-1
between TSCC and corresponding noncancerous tissues
From among the 40 patients with TSCC whose fresh-
frozen tumor specimens were available for the present
study, corresponding noncancerous mucosal tissues were
also collected in 20 patients. In these paired samples, asshown in Table 1, the Wilcoxon signed rank-sum test re-
vealed that the mRNA expression level of Cox-2 was sig-
nificantly higher in the TSCC tissues than in the adjacent
noncancerous mucosal tissues (median values, 5.865 vs.
3.707, p = 0.018). In contrast, the CDH-1 mRNA expres-
sion level was significantly lower in the TSCC tissue than
in the noncancerous mucosal tissue (median values,
11.249 vs. 17.639, p = 0.024). However, no significant in-
verse correlation between Cox-2 and CDH-1 expression
was observed in these samples, or only in 40 TSCC
tissues.
Correlations between the mRNA expression levels of each
gene and clinicopathological factors
We evaluated the correlations between the mRNA ex-
pression levels of each gene in the TSCC tissues and the
clinicopathological factors of the 40 patients with TSCC,
Table 1 Comparison of gene expression levels between




tissue (n = 20)
p valuea
Cox-2 median 5.865 3.707 0.018*
(range) (0.427 - 52.766) (0.394 - 24.626)
CDH-1 median 11.249 17.639 0.024*
(range) (0.048 - 24.494) (2.321 - 36.348)
aWilcoxon signed rank sum test.
*Statistically significant.
TSCC = tongue squamous cell carcinoma.
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was significantly correlated with lymph node metastasis
(p = 0.037), while lower CDH-1 expression was corre-
lated with both advanced T-classification (p = 0.041) and
lymph node metastasis (p = 0.020). Although the mRNA
expressions of SIP1, Snail, and Twist were associated
with neither lymph node metastasis nor T-classification,
higher expression of each of these three genes was sig-
nificantly correlated with the histological grade (p =
0.004, 0.021, and 0.019, respectively). Higher expressions
of SIP1 and Twist were also correlated with perineural
invasion (p = 0.016 and 0.008, respectively). None of the
genes examined were associated with other clinicopatho-
logical factors, including age, gender, vascular invasion,
and lymphatic invasion.
Univariate and multivariate analyses of risk factors
affecting lymph node metastasis
To determine the risk factors predictive of lymph node
metastasis, we further examined the correlation of
lymph node metastasis with other clinicopathological
factors. As shown in Table 3, advanced T-classification
was significantly correlated with lymph node metastasis
(p = 0.036). All other clinicopathological factors showed
no significant correlation with lymph node metastasis,
although lymphatic invasion tended to be associated
with lymph node metastasis (p = 0.069).
We used a multiple logistic regression model to fur-
ther analyze the variables that were significantly corre-
lated with lymph node metastasis in the aforementioned
univariate analyses. As shown in Table 4, lower CDH-1
mRNA expression alone, and not Cox-2 mRNA expres-
sion or T-classification, was found to be the independent
risk factor affecting lymph node metastasis in this series
(odds ratio = 0.905, p = 0.041).
Discussion
Our in vitro results revealed that, in HNSCC cells, the
selective Cox-2 inhibitors led to the suppression of the
EMT by restoring the expression of E-cadherin through
the downregulation of its transcriptional repressors.
Moreover, the extent of the effect of Cox-2 inhibitionwas shown to depend on the baseline expression levels
of both E-cadherin and Cox-2 in each cell; i.e., tumor
cells expressing lower E-cadherin and higher Cox-2 are
expected to be more sensitive to Cox-2 inhibition in
terms of the restoration of E-cadherin expression. Such
a finding is consistent with a previous study of bladder
cancer cells using another Cox-2 inhibitor, etodolac. In
that study, etodolac upregulated E-cadherin expression
only in T24 cells, which express the highest level of
Cox-2 and the lowest level of E-cadherin; it did not do
so in 5637 cells or K47 cells, which express a lower level
of Cox-2 and a higher level of E-cadherin [42]. Interest-
ingly, using the same three bladder cancer cell lines and
three different Cox-2 inhibitors (etodolac, celecoxib, and
NS-398), Adhim et al. found that E-cadherin mRNA was
enhanced in all three cell lines by at least two Cox-2 in-
hibitors in each cell line, although the fold of increase
remained the highest in T24 cells [43]. These and our
results suggests that the suitability of Cox-2 inhibitor ap-
plication could be assessed by predicting its anti-cancer ef-
fects in advance based on the baseline expression level of
Cox-2 and certain of its downstream effector molecules.
Aside from the use of Cox-2 inhibitors, the Cox-2-
dependent regulation of E-cadherin expression in HNSCC
cells was demonstrated in a study using KB cells trans-
fected with Cox-2 cDNA and gene silencing with Cox-2
siRNA, although the specific signaling pathway between
Cox-2 and E-cadherin was not referred to [45]. In HNSCC
cells, St. John et al. elucidated that proinflammatory cyto-
kine IL-1β induces downregulation of E-cadherin through
the Cox-2/Snail pathway, which is blocked by the selective
Cox-2 inhibition using celecoxib or Cox-2 small hairpin
RNA [44]. Those findings also corroborate our results
regarding the Cox-2 inhibition-induced restoration of
E-cadherin expression in HNSCC.
Regarding the direct mechanisms underlying the down-
regulation of E-cadherin, it has been suggested that tran-
scriptional repression and promoter hypermethylation are
primarily responsible in sporadic carcinoma, whereas
other mechanisms such as genomic deletion and loss of
heterozygosity associated with germline mutation are ob-
served in hereditary carcinoma [6-8]. According to the
study that examined CpG island methylation around the
promoter region of CDH-1 in HNSCC cell lines by
methylation-specific PCR, the methylation was partially
found in the HSC-2 cells, but not in the HSC-4 cells [46],
which may also accounts for the low base-line expression
of E-cadherin in the HSC-2 cells.
In our present in vitro study, the mRNA expression
level of SIP1, but not those of Snail or Twist, showed a
significant inverse correlation with that of CDH-1, which
is in agreement with previous findings in HNSCC,
breast, and hepatocellular carcinoma cells [9,47-49]. We
observed that the SIP1 expression was also significantly
Table 2 Correlation between gene expression levels and clinicopathological factors
Variable n Cox-2 p value SIP1 p value Snail p value Twist p value CDH-1 p value
Agea < 60 25 median 3.964 0.583 3.191 0.773 1.071 0.273 12.469 0.119 13.681 0.878
(range) (0.640 - 61.171) (0.035 - 17.376) (0.020 - 6.229) (0.000 - 64.312) (0.100 - 45.381)
≧ 60 15 median 4.443 2.926 0.936 6.947 13.881
(range) (0.427 - 52.766) (0.059 - 9.482) (0.099 - 2.361) (0.936 - 20.548) (0.841 - 24.494)
Gendera Male 35 median 4.037 0.817 3.200 0.247 0.986 0.611 9.794 0.746 12.670 0.379
(range) (0.427 - 61.171) (0.035 - 17.376) (0.020 - 6.229) (0.000 - 64.312) (0.100 - 45.381)
Female 5 median 4.331 1.454 1.191 9.102 19.520
(range) (3.223 - 6.581) (0.677 - 7.218) (0.562 - 2.361) (5.989 - 12.900) (5.367 - 23.448)




LN metastasisa N (-) 15 median 2.399 0.037* 2.926 0.964 0.983 0.800 6.947 0.226 18.801 0.020*
(range) (0.427 - 6.092) (0.059 - 11.250) (0.193 - 5.137) (0.000 - 42.360) (0.841 - 45.381)
N (+) 25 median 4.443 3.602 1.094 12.037 10.688
(range) (1.379 - 61.171) (0.035 - 17.376) (0.020 - 6.229) (0.936 - 64.312) (0.100 - 23.697)
Histological gradeb I 21 coefficient rs = 0.155 0.338 rs = 0.462 0.004* rs = 0.374 0.021* rs = 0.381 0.019* rs = -0.026 0.873
II 12
III 7
Vascular invasiona Negative 32 median 3.478 0.133 3.393 0.360 1.006 0.608 9.369 0.913 14.999 0.085
(range) (0.640 - 61.171) (0.035 - 17.376) (0.020 - 5.538) (0.000 - 64.312) (0.100 - 45.381)
Positive 8 median 10.759 2.250 1.264 9.794 7.799
(range) (0.427 - 43.355) (0.059 - 6.356) (0.193 - 6.229) (1.246 - 29.053) (0.841 - 23.697)
Lymphatic invasiona Negative 22 median 4.037 0.800 3.939 0.195 0.936 0.554 9.027 0.554 15.966 0.192
(range) (0.640 - 61.171) (0.035 - 11.250) (0 020 - 5.137) (0.000 - 64.312) (1.373 - 38.234)
Positive 18 median 4.733 2.155 1.104 10.915 10.694
(range) (0.427 - 60.921) (0.059 - 17.376) (0.086 - 6.229) (0.936 - 31.933) (0.100 - 45.381)
Perineural invasiona Negative 30 median 4.128 0.841 2.212 0.016* 1.006 0.286 7.720 0.008* 14.891 0.617
(range) (0.427 - 61.171) (0.035 - 11.250) (0.020 - 5.137) (0.000 0 64.312) (0.100 - 38.234)
Positive 10 median 5.247 6.345 1.114 13.886 11.907
(range) (0.640 - 60.921) (2.250 - 17.376) (0.458 - 6.229) (9.027 - 31.933) (2.089 - 45.381)
aMann-Whithey U test, bSpearman rank correlation coefficient.
*Statistically significant.

















Table 3 Univariate analysis of clinicopathological factors predictive of lymph node metastasis
Variable n LN metastasis (-) n = 15 LN metastasis (+) n = 25 p value
Agea < 60 25 9 (36.0%) 16 (64.0%) 0.724
≧ 60 15 6 (40.0%) 9 (60.0%)
Gendera Male 35 15 (42.9%) 20 (57.1%) 0.081
Female 5 0 (0.0%) 5 (100.0%)
T classificationb 1 2 1 (50.0%) 1 (50.0%) 0.036*
2 10 7 (70.0%) 3 (30.0%)
3 22 4 (18.2%) 18 (81.8%)
4 6 3 (50.0%) 3 (50.0%)
Histological gradeb I 21 7 (33.3%) 14 (66.7%) 0.551
II 12 6 (50.0%) 6 (50.0%)
III 7 2 (28.6%) 5 (71.4%)
Vascular invasiona Negative 32 13 (40.6%) 19 (59.4%) 0.350
Positive 8 2 (25.0%) 6 (75.0%)
Lymphatic invasiona Negative 22 11 (50.0%) 11 (50.0%) 0.069
Positive 18 4 (22.2%) 14 (77.8%)
Perineural invasiona Negative 30 13 (43.3%) 17 (56.7%) 0.174
Positive 10 2 (20.0%) 8 (80.0%)
aFisher’s exact test, bChi-square test.
*Statistically significant.
LN = lymph node.
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SIP1 acts as a principal effector in the Cox-2-dependent
regulation of E-cadherin expression in HNSCC. How-
ever, the Cox-2 inhibitors used in the present study led
to the downregulation of not only SIP1 but also Snail
and Twist comparably, indicating the similar importance
of each transcriptional repressor in this pathway. In
NSCLC cells, ZEB1 and Snail were found to be repres-
sors responsible for the regulation of E-cadherin down-
stream of Cox-2/PGE2 [37], whereas in bladder cancer
cells Cox-2 inhibitors downregulated all of the E-
cadherin repressors examined: Snail, Slug, Twist, and
ZEB1 [43]. Aside from the implication of Cox-2, in
breast cancer cells, receptor activator of NF-κB ligand
(RANKL) was revealed to downregulate the E-cadherin
expression by activating the NF-κB pathway and enhan-
cing Snail and Twist expression [50]. In HNSCC cells,
inhibition of Akt activity was shown to decrease NF-κB
signaling, thereby downregulate the expression of Snail
and Twist, but not SIP-1, to induce the mesenchymal-Table 4 Multivariate analysis of factors predictive of
lymph node metastasis
Variable Odds ratio 95% confidence interval p valuea
T-classification 1.119 0.418 - 2.993 0.823
Cox-2 1.011 0.965 - 1.060 0.648
CDH-1 0.905 0.822 - 0.996 0.041*
aMultiple logistic regression model.
*Statistically significant.to-epithelial reverting transition [51]. Although we did
not evaluate the expressions of ZEB1 and Slug, our re-
sults verified these reports in terms of the direct role of
transcriptional repressors in the Cox-2-dependent regu-
lation of E-cadherin.
In addition to the suppression of the EMT, some other
anti-cancer effects of Cox-2 inhibitors in HNSCC have
been reported, which include the inhibition of VEGF-A
expression by celecoxib [15], the suppression of invasive-
ness by NS-398 [52,53] and celecoxib [54], the inhibition
of proliferation by celecoxib, NS-398, nimesulide, and
meloxicam [54,55], and the induction of apoptosis by
celecoxib [55]. Since a close relationship is likely be-
tween the EMT and enhanced cell migration, the Cox-2
inhibitor-induced suppression of the EMT may also con-
tribute to the attenuation of the invasiveness of cancer
cells. Considering the multifaceted function of Cox-2 it-
self, a variety of mechanisms are thought to be involved
in the anti-cancer effects of selective Cox-2 inhibitors,
and these mechanisms are presumed to exert their ef-
fects cooperatively.
In the clinical samples that we examined, compared to
adjacent noncancerous mucosal tissue, the mRNA ex-
pression level of CDH-1 was significantly lower in the
TSCC tissue as expected, although functional E-cadherin
is supposed to be assessed by its membranous expres-
sion. In addition, we found that the mRNA expression
level of Cox-2 was significantly higher in the TSCC tis-
sue, which is consistent with the previous studies
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possible inverse correlation between Cox-2 and E-
cadherin expressions, we found a trend toward an in-
verse correlation in the HNSCC cell lines examined,
whereas no correlation was observed in the clinical sam-
ples of TSCC. Inconsistent statistical results have been
reported even in immunohistochemical evaluations of
cancers other than HNSCC: although a significant in-
verse correlation between Cox-2 and E-cadherin expres-
sions was seen in bladder cancer [41], no correlation
between them was revealed in gastric cancer [40], the
latter of which is in agreement with our result assessed
by quantitative real-time PCR. Such discrepancies could
be attributed not only to differences in the sites of can-
cer origin and sample size, but also to differences in the
studies’ evaluation methods and statistical methods.
Aside from these statistical analyses, an inverse expres-
sion pattern between Cox-2 and E-cadherin in each of
individual cases was seen by immunohistochemical
observation in NSCLC and colon cancer [37,56]. Con-
sidering tissue heterogeneity in terms of the localized
expression of particular molecules along with the above-
mentioned immunohistochemical observation, we specu-
late that the extent of the upregulation of Cox-2 and its
possible downregulation of E-cadherin may depend on
microscopically specific sites such as the invasive front or
the inside of cancer nests, which would not necessarily be
reflected in any statistical analysis or in homogenized sam-
ples at all.
Regarding the correlations with clinical parameters in
TSCC, while univariate analysis demonstrated that the
mRNA expressions of both higher Cox-2 and lower
CDH-1 were significantly correlated with lymph node
metastasis, the multivariate analysis revealed that a lower
CDH-1 mRNA expression level was the only independ-
ent predictor of lymph node metastasis in this cohort.
These results suggest that the induction of the EMT, re-
gardless of dependency on its various upstream path-
ways, is closely implicated in the development of
lymphogeneous metastasis. However, the predictive reli-
ability of a lower CDH-1 mRNA expression level should
be further validated using much larger independent co-
horts. The result regarding Cox-2, even though it was
confined to the univariate analysis, is in accord with the
preceding immunohistochemical studies of HNSCC, al-
though those were also missing multivariate analysis
[15,16]. Considering its role in the regulation of E-
cadherin expression, Cox-2 is thought to indirectly con-
tribute to lymph node metastasis, at least in part
through the induction of the EMT. On the other hand,
our result regarding CDH-1 is consistent with the previ-
ous immunohistochemical studies of oral SCC that re-
ported a significant correlation between reduced E-
cadherin expression and lymph node metastasis [57-60],but not with others that showed no correlation between
them [61-63], although all of those studies lacked multi-
variate analysis. These contradictory results seemed to
be attributable to the quite variable criteria used to
evaluate the extent of immunostaining intensity, which
inevitably seems prone to subjective judgment. In
addition, since each tumor specimen consists of het-
erogeneous cancer cell populations that show different
behaviors, staining scores could vary depending on the
tumor portion selected for examination. To overcome
such uncertainties accompanying immunohistochemical
evaluation, instead we quantified mRNA expression
levels in homogenates from whole frozen blocks of
tumor samples. However, those data must still be
interpreted cautiously because the differences in ex-
pression levels according to microscopically distinct
sites and cellular localization cannot be considered,
and it is thus possible that certain correlations would
be missed.
Practically, if clinical N0 (cN0) patients with occult
lymph node metastasis can be discriminated accurately
from other cN0 patients, we could apply neck dissection
exclusively for those selected patients in advance of the
inevitable development of delayed neck metastasis.
Therefore, from a clinical point of view, the prediction
of lymph node metastasis is genuinely meaningful in
cN0 cases. Among the reliable studies conducted to
identify predictive markers of delayed or occult neck
metastasis within clinical stage I/II (cT1-2 N0) oral squa-
mous cell carcinoma by a multivariate analysis, tumor
thickness or depth has been most accepted as an inde-
pendent histopathological parameter [64]. However, the
downregulation of E-cadherin was recently revealed by
us and others to be one of the independent molecular
predictors of delayed neck metastasis even in such a lim-
ited patient population [9,65,66]. These previous and
present results suggest that the restoration of E-cadherin
expression by inhibiting any of the upstream signals pro-
moting the EMT may prevent the initiation and progres-
sion of lymph node metastasis of HNSCC. Further
investigations are indispensable to establish the optimal
standard to evaluate the risk of metastasis using molecu-
lar markers related to the EMT.
In conclusion, our findings suggest that the downregula-
tion of CDH-1 resulting from the induction of the EMT is
closely involved in lymph node metastasis in HNSCC. The
expression profiles of EMT-related molecular makers in
primary tumors are thought to be informative to predict
the clinicopathological behavior of HNSCC. In addition,
the appropriately selective administration of selective
Cox-2 inhibitors may lead to an anti-metastatic effect as
suppression of the EMT by restoring E-cadherin expres-
sion through the downregulation of its transcriptional re-
pressors, cooperatively with various other mechanisms.
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